PRTA Stock Risk & Deep Value Analysis

Prothena Corporation plc

DVR Score

7.2

out of 10

Solid Pick

The Bottom Line on PRTA

We analyzed Prothena Corporation plc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PRTA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 25, 2025•Run Fresh Analysis →

📈PRTA Performance Overview3yr weekly

📊

Unlock PRTA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

PRTA Deep Value Analysis

Prothena exhibits significant 10x potential by targeting massive neurodegenerative markets (Alzheimer's, Parkinson's) with deep scientific expertise in misfolded proteins and validated through strong partnerships with BMS and Novo Nordisk. A robust cash position (~$460M) provides ample runway. The primary catalyst is the mid-2025 Birtamimab Phase 3 data for AL amyloidosis, which could unlock a multi-billion dollar market. Red flags include prior clinical setbacks (Birtamimab's initial trial failure, Roche's decision on Prasinezumab) and the notoriously high failure rates in neuroscience drug development. Its path to profitability is highly binary and contingent on successful trial outcomes, presenting substantial risk of loss if key programs fail.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on PRTA

Create a free account to set price alerts and get notified on Telegram when PRTA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Prothena Corporation plc (PRTA)?

As of September 25, 2025, Prothena Corporation plc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the PRTA DVR analysis updated?

Our AI-powered analysis of Prothena Corporation plc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 25, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.